GBC AG sets MustGrow Biologics price target at CAD 2.51, keeps Buy rating
Bitget2026/09/28 08:00- GBC AG reiterated a Buy on MustGrow Biologics, cutting its target price to CAD 2.51 from CAD 2.70.
- Report cited a first Bayer development milestone, generating CAD 1.36 million of high-margin license revenue in H1 2026.
- TerraSante sales hit about CAD 830,400 by mid-August, up 46% versus full-year 2025, constrained by production ramp delays.
- FY2026 revenue forecast cut to CAD 3.5 million from CAD 4.5 million; EBITDA seen at CAD -4.58 million.
- GBC kept FY2027 revenue at CAD 14.05 million, FY2028 at CAD 31.56 million; EBITDA forecast at CAD -1.08 million, then CAD 8.46 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The EU questions why a certain exchange continues to operate after being asked to exit
How Strategy keeps STRC near $100 while MSTR stock swings
WTI Crude Oil Drops Over 1.00% Today, Currently at $88.55 per Barrel
Summary of the Bank of Japan's September meeting opinions: Majority of members advocate for continued rate hikes, some call for acceleration.
The summary of the Bank of Japan's September meeting opinions shows that some policymakers believe it is necessary to accelerate interest rate hikes or bring rates closer to the central bank's "target" as soon as possible, increasing the likelihood of further rate hikes.
Crypto prices
More
